• A Mukhopadhyay, S Dasgupta, U Kanti Ray, F Gharami, C K Bose, and S Mukhopadhyay.
• Department of Haemato-Oncology, Netaji Subhas Chandra Bose Cancer Research Institute, 16 A Park Lane, Kolkata, 700016, India, molecularbiology.ncri@gmail.com.
• Ir J Med Sci. 2015 Mar 1; 184 (1): 183-8.

IntroductionImatinib is a first-line therapy to treat chronic myeloid leukemia (CML) patients.Materials And MethodsWe selected 22 CML cases of pregnancies and reported 9 accidental and 13 planned pregnancies that were on imatinib therapy. Willing female patients remaining in complete hematological, cytogenetic and major molecular responses for at least 2 years planned for pregnancy and were advised to stop imatinib for 1 month prior to conception and 3 months after conception (first trimester). Willing male patients stopped therapy 1 month prior to conception of their wives. In unplanned cases, all patients were in exposure to imatinib during conception. Twenty-two pregnancies resulted in seven male children and eight female children. There were three spontaneous abortions and four elective abortions along with one case of hypospadia and another one of mild hydrocephalus.ConclusionWe may suggest that planned pregnancy during therapy may be encouraged but imatinib therapy in unplanned pregnancy can cause spontaneous abortion or congenital anomaly.

29 keywords...

hide…